Efficacy and safety of aspirin in the long-term management of atherothrombosis

Haematologica

Volumn 87, Issue 1, 2002, Pages 6-8

  Patrono, Carlo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ETORICOXIB; LUMIRACOXIB; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB; UNCLASSIFIED DRUG; VALDECOXIB;

ANTICOAGULANT THERAPY; ATHEROSCLEROSIS; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG SAFETY; DRUG SELECTIVITY; DRUG SPECIFICITY; HUMAN; LONG TERM CARE; META ANALYSIS; PROSTAGLANDIN SYNTHESIS; RISK BENEFIT ANALYSIS; SHORT SURVEY; THROMBOSIS; TREATMENT FAILURE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTERIOSCLEROSIS; ASPIRIN; BLOOD PLATELETS; CARDIOVASCULAR DISEASES; CEREBROVASCULAR ACCIDENT; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DRUG EVALUATION; DRUG RESISTANCE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMANS; ISOENZYMES; MALE; MEMBRANE PROTEINS; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RISK; SAFETY; THROMBOSIS;

EID: 0036154283     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (21)

1. Platelet-active drugs: The relationships among dose, effectiveness, and side effects
2. Prevention of death, mycardial infraction and stroke by antiplatelet theraphy: Collaborative meta-analysis of 266 trials involving 200,000 patients at high risk of occlusive vascular events
3. The risk of upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetaminophen, and combination of these agents
4. Aspirin as an antiplatelet drug
5. Determination of who may derive most benefit from aspirin in primary prevention: Subgroup results from a randomized controlled trial
6. Aspirin for primary prevention of coronary heart disease: Safety and absolute benefit related to coronary risk derived from meta-analysis of randomized trials
7. Low-dose aspirin and vitamin E in people at cardiovascular risk: A randomized trial in general practice
8. Profile and prevalence of aspirin resistance in patients with cardiovascular disease
9. Aspirin resistance coincides with platelet COX-2 expression but not with enhanced esterase activity
10. Increased platelet sensitive to collagen in individuals resistant to low-dose aspirin
11. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin
12. The Coxibs, selective inhibitors of cyclooxygenase-2
13. Estimated rate of thromboxane secretion into the circulation of normal man
14. Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women
15. Risk of cariovascular events associated with selective COX-2 inhibitors
16. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis
17. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS Study: A randomized controlled trial
18. Selective cyclooxygenase-2 inhibition by nimesulide in man
19. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2
20. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib
21. Cyclooxygenase-selective inhibition of prostanoid formation: Transducing biochemical selectivity in to clinical readouts